Andrew is a senior M&A and equity capital markets lawyer with extensive experience in public and private mergers and acquisitions, IPOs and secondary offerings, joint ventures and private financing rounds.
He is one of only six London lawyers to be ranked in Tier 1 for mid-market M&A by Chambers UK legal directory as well as being listed as one of The Lawyer's Hot 100. As quoted in the legal directories, Andrew's clients describe him as 'a strong negotiator and problem solver' as well as being 'Incredibly pragmatic. The perfect sounding board for our business.'
Andrew is the UK Head of Corporate Life Sciences and is recognised within the legal directories as a 'very talented' corporate and commercial lawyer with a long-standing commitment to the biotechnology and pharmaceutical industries.
While at his previous firm, Andrew led the team on the contested public takeover of his long-standing client Lavendon Group plc, a transaction which garnered industry recognition at The Legal Business Awards.
|Since 2021||Partner, Taylor Wessing|
|2010 - 2021||Partner and Head of Corporate (2014 - 2020), Stephenson Harwood LLP|
|2002 - 2010||Partner, Ashurst LLP|
|1994 - 2002||Associate, Ashurst Morris Crisp|
|1992 - 1994||Articled Clerk, Ashurst Morris Crisp|
|1994||Admitted as a lawyer, England and Wales|
|1987 - 1990||University of Birmingham, LLB Law|
Aktuelle News & Insights
Shield Therapeutics enters transformational collaboration agreement with Viatris and raises debt and equity finance
von Andrew Edge
Recognition for our expertise as Life Sciences Team of the Year
von mehreren Autoren
Aspen Healthcare sold to Canadian-based property trust
von Andrew McLean und Andrew Edge
Advising Apollo Therapeutics on $145 million financing
von Andrew Edge und Chris Cowley
Olena Stakhurska, LL.M.